Bausch Health Cos (BHC) Expected to Announce Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is expected to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Bausch Health Cos to announce earnings of $0.96 per share and revenue of $2.5564 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. On average, analysts expect Bausch Health Cos to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Cos Stock Down 3.3%

BHC stock opened at $4.53 on Wednesday. The firm has a 50 day moving average of $5.05 and a 200 day moving average of $5.60. The stock has a market capitalization of $1.69 billion, a PE ratio of -1.40 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 52 week low of $4.33 and a 52 week high of $8.69.

Insider Activity

In related news, Director Frank D. Lee sold 24,456 shares of Bausch Health Cos stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the sale, the director owned 49,339 shares of the company’s stock, valued at $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Paulson & CO. Inc. raised its position in Bausch Health Cos by 3.5% during the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock worth $509,128,000 after buying an additional 2,500,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Bausch Health Cos by 65.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after acquiring an additional 2,038,813 shares during the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Bausch Health Cos in the 2nd quarter valued at $22,644,000. Dimensional Fund Advisors LP increased its stake in shares of Bausch Health Cos by 8.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,253,995 shares of the company’s stock worth $22,616,000 after acquiring an additional 241,546 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Bausch Health Cos by 8.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,045,737 shares of the company’s stock worth $14,223,000 after acquiring an additional 151,658 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Wall Street Analysts Forecast Growth

BHC has been the topic of a number of recent analyst reports. Royal Bank Of Canada cut their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Weiss Ratings downgraded shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $8.00.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.